Phosphodiesterase 4 (PDE4) inhibitors, in view of their antiinflammatory effects, have recently been confirmed as a potential novel therapeutic approach for the treatment of exacerbations in COPD [16]. This evidence concerns the gene PDE4A and chronic obstructive pulmonary disease.